News
Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...
So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results